$20.24
2.82% today
Nasdaq, Feb 05, 04:48 pm CET
ISIN
US04280A1007
Symbol
ARWR

Arrowhead Pharmaceuticals, Inc. Stock price

$19.68
+0.18 0.92% 1M
-5.40 21.53% 6M
+0.88 4.68% YTD
-12.34 38.54% 1Y
-30.07 60.44% 3Y
-24.22 55.17% 5Y
+13.47 216.91% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.94 5.02%
ISIN
US04280A1007
Symbol
ARWR
Sector
Industry

Key metrics

Market capitalization $2.46b
Enterprise Value $2.64b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 743.10
P/S ratio (TTM) P/S ratio 693.36
P/B ratio (TTM) P/B ratio 13.20
Revenue growth (TTM) Revenue growth -98.52%
Revenue (TTM) Revenue $3.55m
EBIT (operating result TTM) EBIT $-601.08m
Free Cash Flow (TTM) Free Cash Flow $-604.32m
Cash position $680.96m
EPS (TTM) EPS $-5.00
P/E forward negative
P/S forward 7.84
EV/Sales forward 8.40
Short interest 8.91%
Show more

Is Arrowhead Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Arrowhead Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

9x Buy
64%
5x Hold
36%

Analyst Opinions

14 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

Buy
64%
Hold
36%

Financial data from Arrowhead Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.55 3.55
99% 99%
100%
- Direct Costs 19 19
49% 49%
524%
-15 -15
107% 107%
-424%
- Selling and Administrative Expenses 78 78
0% 0%
2,204%
- Research and Development Expense 489 489
43% 43%
13,781%
-582 -582
203% 203%
-16,408%
- Depreciation and Amortization 19 19
49% 49%
524%
EBIT (Operating Income) EBIT -601 -601
193% 193%
-16,932%
Net Profit -599 -599
192% 192%
-16,887%

In millions USD.

Don't miss a Thing! We will send you all news about Arrowhead Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arrowhead Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
14 days ago
NEW YORK , Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE: GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE: B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE: APO) is acquiring Barn...
Neutral
Business Wire
14 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentatio...
Neutral
Business Wire
19 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action dat...
More Arrowhead Pharmaceuticals, Inc. News

Company Profile

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Head office United States
CEO Christopher Anzalone
Employees 609
Founded 1989
Website www.arrowheadpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today